Biovail reports record 1999 4th qtr/year-end results

April 2000
Biotech Financial Reports;Apr2000, p2
Trade Publication
Reports that Toronto, Ontario-based biotechnology company Biovail Corp. International has announced record earnings during the fourth quarter of 1999. Percentage increase in the company's earnings during the fourth quarter of 1999 as compared to that of the same period in 1998; Net income and net losses; Factors attributing to the improved profitability of the company in 1999.


Related Articles

  • It's kill and cure in pharma sales.  // Marketing Week;7/17/2003, Vol. 26 Issue 29, p16 

    Comments on the marketing strategy used by Biovail Corp., which sells anti-hypertension products during a cardiology conference in Great Britain.

  • Biotech Earnings Show Positive Rebound During Second Quarter. Mirasol, Feliza // Chemical Market Reporter;07/24/2000, Vol. 258 Issue 4, p13 

    Focuses on the earnings of biotechnology companies in the second quarter of 2000. Companies that reported growth in the quarter; Reasons for their revenue growth.

  • Biotech industry tries to recover from 2-year lull. Brower, Vicki // JNCI: Journal of the National Cancer Institute;3/5/2003, Vol. 95 Issue 5, p348 

    Looks at the financial performance of the biotechnology industry in the U.S. Role of the corporate side of biotechnology firms in the downward turn of the industry; Advantage of biotechnology drugs over technology products in terms of long-term investment; Effect of cancer drug approval on...

  • The Widening Gap Between Major and Emerging Biotech Players. Van Arnum, Patricia // Chemical Market Reporter;6/16/2003, Vol. 263 Issue 24, pFR2 

    Examines the widening revenue gap between major and emerging biotechnology companies. Sales of leading products in emerging biotech sector; Revenue for leading therapeutic proteins; Factors affecting the performance of the industry.

  • FINANCINGS ROUNDUP.  // BioWorld Today;6/11/2009, Vol. 20 Issue 111, p6 

    This section offers news briefs concerning finance in the biotechnology sector as of June 2009. A three-year $410 million revolving credit facility was obtained by Biovail Corp. from a syndicate of banks. The senior secured convertible notes of Generex Biotechnology Corp. issued in March 2008 to...

  • Biovail files NDA for novel dosage form of anti-depressant.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p12 

    Reports on the acceptance of the U.S. Food and Drug Administration to Biovail Corp.'s submission of a new drug application for a novel dosage format of citalopram for the treatment of depression. Product offering; Characterization of citalopram hydrobomide; Market penetration of citalopram.

  • WALL ST./FINANCE.  // MondayMorning;8/10/2009, Vol. 17 Issue 30, p3 

    This section offers news briefs on business and finance in the U.S. as of August 2009. The economy's problem of the country on unemployment showed the first signs of easing. The Dow Jones industrial average closed at 198.46, or 2.2 percent, at 9,370,07. Biovail Corp. increased its second-quarter...

  • Public biotech 2000?the numbers. Lähteenmäki, Riku; Fletcher, Liz // Nature Biotechnology;May2001, Vol. 19 Issue 5, p407 

    Reports on the performance of biotechnology companies during the year 2000. Number of private biotechnology companies which became public companies; Statistics for total revenue, research and development spendings, profit and loss for the companies in the duration; Names of the top 10...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/14/2008, Vol. 19 Issue 72, p3 

    This section offers news briefs on the biotechnology industry. David J. Masso has resigned as president, CEO, and as a member of the board of directors of AEterna Zentaris Inc. Eugene Melnyk, former chairman and CEO of Biovail Corp., has withdrawn an application to the Ontario Supreme Court of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics